EMVERM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Emverm, and when can generic versions of Emverm launch?
Emverm is a drug marketed by Impax Labs Inc and is included in one NDA.
The generic ingredient in EMVERM is mebendazole. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the mebendazole profile page.
Summary for EMVERM
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 142 |
Patent Applications: | 3,604 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for EMVERM |
DailyMed Link: | EMVERM at DailyMed |
Pharmacology for EMVERM
Drug Class | Anthelmintic |
Anatomical Therapeutic Chemical (ATC) Classes for EMVERM
US Patents and Regulatory Information for EMVERM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Impax Labs Inc | EMVERM | mebendazole | TABLET, CHEWABLE;ORAL | 073580-001 | Jan 4, 1995 | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |